Your Messages Inbox
Your Article Summary
See Latest ArticlesWatsons GELNIQUE (oxybutynin chloride) Gel 10% Approved by FDA for the Treatment of Overactive Bladder
Watson Pharmaceuticals, 01/28/09
Watson Pharmaceuticals, Inc., a leader in generic and specialty branded pharmaceuticals, announced that the U.S. Food and Drug Administration (FDA) has approved GELNIQUE (oxybutynin chloride) Gel 10%, the first and only topical gel for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and frequency. The U.S. OAB market currently exceeds $1.8 billion annually and continues to grow each year.
Today in Drug/Product Approvals...keeping you current
Receive free subspecialty "5-minute updates" via email
Cell Therapeutics Announces FDAs Oncologic Drugs Advisory Committee to Review Pixantrone for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkins Lymphoma, February 2010
Cell Therapeutics, 12/18/09
Eslicarbazepine: A novel antiepileptic agent designed for improved efficacy and safety
Formulary , 12/16/09
Human genome sciences announces submission of marketing authorization application to emea for joulferon
Human Genome Sciences, 12/16/09
Article Search
Sponsor